Literature DB >> 15387374

Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma.

Masanao Saio1, Matt Teicher, Gaynor Campbell, Helen Feiner, Yara Delgado, Alan B Frey.   

Abstract

Deficient expression of HLA class-I molecules observed in many cancers is suggested to influence both disease progression and potential efficacy of T cell-mediated immune therapy. Previous studies have attempted to correlate either primary breast cancer tumor grade with HLA class-I levels or the presence of HLA class-I-deficient cells in metastatic lesions with survival. In this study we evaluated the HLA class-I status of matched primary and secondary breast cancer lesions in order to ask the question: is metastasis of breast cancer associated with down-regulation of HLA class-I expression? Immunocytochemistry analysis shows a definitive correlation between diminished HLA class-I expression and dissemination of breast cancer to tumor-draining lymph nodes: both the total number of HLA class-I+ cells per sample and the levels of expression are dramatically decreased in secondary versus primary tumor lesions. These findings are consistent with the contention that the ability of breast cancer cells to escape the confines of the original tumor lesion requires down-regulation of HLA class-I expression and implies that enhancing HLA class-I expression in secondary breast cancer may have a beneficial effect on T-cell-mediated immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15387374     DOI: 10.1023/b:clin.0000037707.07428.ff

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  13 in total

Review 1.  Immune reaction to breast cancer: for better or for worse?

Authors:  H M Ogmundsdóttir
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2001       Impact factor: 4.291

2.  Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response.

Authors:  Y Sykulev; M Joo; I Vturina; T J Tsomides; H N Eisen
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

3.  HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions.

Authors:  M Vitale; R Rezzani; L Rodella; G Zauli; P Grigolato; M Cadei; D J Hicklin; S Ferrone
Journal:  Cancer Res       Date:  1998-02-15       Impact factor: 12.701

Review 4.  HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.

Authors:  D J Hicklin; F M Marincola; S Ferrone
Journal:  Mol Med Today       Date:  1999-04

5.  Can the HLA phenotype be used as a prognostic factor in breast carcinomas?

Authors:  A Concha; T Cabrera; F Ruiz-Cabello; F Garrido
Journal:  Int J Cancer Suppl       Date:  1991

6.  Interactions between the immune system and breast cancer.

Authors:  H M Ogmundsdóttir; I Pétursdóttir; I Gudmundsdóttir
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

7.  Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival.

Authors:  I Levin; T Klein; J Goldstein; O Kuperman; J Kanetti; B Klein
Journal:  Cancer       Date:  1991-12-15       Impact factor: 6.860

8.  Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer.

Authors:  L Kaklamanis; R Leek; M Koukourakis; K C Gatter; A L Harris
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

9.  Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.

Authors:  H O Wintzer; M Benzing; S von Kleist
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

10.  Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma.

Authors:  J R Goepel; R C Rees; K Rogers; C J Stoddard; W E Thomas; L Shepherd
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

View more
  4 in total

1.  A novel role of HLA class I in the pathology of medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Bhargavi Rajan; Elisabeth J Rushing; Mi Rim Choi; Brian R Rood; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Transl Med       Date:  2009-07-12       Impact factor: 5.531

Review 2.  The immunoregulatory mechanisms of carcinoma for its survival and development.

Authors:  Caigan Du; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-01-21

3.  MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.

Authors:  Irene Romero; Cristina Garrido; Ignacio Algarra; Virginia Chamorro; Antonia Collado; Federico Garrido; Angel M Garcia-Lora
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

Review 4.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Authors:  Karthik Dhatchinamoorthy; Jeff D Colbert; Kenneth L Rock
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.